Ashley Cox
Partner, Head of Europe
Expertise:
Ashley comes to EVERSANA as 파트너 (Partner), Head of Europe, from SmartAnalyst where she was Head of European Business Development. In this role, she led business development activities across Europe, with a focus on developing disease, asset, and portfolio strategies at the earlier stages of clinical development. Prior to SmartAnalyst, Ashley was Vice President at PharmaVentures, Ltd., a boutique corporate advisory firm that represents mostly sell-side opportunities for both partnering and divestment to global and regional pharmaceutical organizations. There, she was responsible for leading cross-functional teams to deliver valuations, lead transaction activities, and develop a new strategic consulting vertical.
Earlier in her career, Ashley was Head of Global Business Development for the Prescient Healthcare Group, with a strong focus on Competitive Intelligence and Business Analytics. Ashley has supported decision-making across the majority of the top 20 pharma and many biotech companies. She started her career as a Medical Representative and has held a variety of commercial and licensing roles across the pharmaceutical and generics sectors.
Ashley is the President of the London Chapter of the Healthcare Businesswomen’s Association (HBA), an organisation striving for gender parity, diversity, equity and inclusion. Ashley is ABPI qualified and holds an MSc. in Pharmaceutical Analysis from the University of Strathclyde and a BSC. (Hons) in Neuroscience from the University of Glasgow.
Articles by Ashley Cox
Unlocking Success: Exploring Critical Factors for Launching Orphan Drugs
A Conversation with Ashley Cox, Senior Principal, Head of Europe, EVERSANA MANAGEMENT CONSULTING, and Sid Agrawal, Senior Principal, EVERSANA MANAGEMENT CONSULTING Join Ashley Cox, Senior Principal and Head of Europe, and Sid Agrawal, Senior Principal, as they delve into the realm of orphan drugs. With 6,424 designations granted since 1983 and 1,085 products receiving FDA […]
Successfully Navigating Self-Commercialisation in Europe
Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of […]
Successful Launches in Europe: Complex, but Not Complicated?
Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical and biotechnology companies looking to maximise their revenue consider Europe to be a key focus[1]. Indeed, looking at first-time […]